News >

NICE Rejects Treatments for Bladder and Thyroid Cancer

Jason Harris
Published: Friday, Oct 20, 2017

The UK’s National Institute for Health and Care Excellence (NICE) has issued guidelines recommending against nivolumab (Opdivo) for routine use in patients with previously-treated advanced urothelial carcinoma. The agency also recommended against lenvatinib (Lenvima) and sorafenib (Nexavar) for patients with advanced, unresectable metastatic thyroid cancer.

NICE is still accepting comments on the drug proposals until November 9 and will issue a second appraisal of the applications November 23.


  1. Galsky MD, Retz M, Siefker-Radtke AO, et al. Efficacy and safety of nivolumab monotherapy in patients with metastatic urothelial cancer (mUC) who have received prior treatment: Results from the phase II CheckMate-275 study. Presented at: 2016 ESMO Congress; October 7-11, 2016; Copenhagen, Denmark. Abstract LBA31.
  2. Sharma P, Bono P, Kim JW, et al. Efficacy and safety of nivolumab monotherapy in metastatic urothelial cancer (mUC): results from the phase I/II CheckMate 032 study. J Clin Oncol 34, 2016 (suppl; abstr 4501).
  3. Gianoukakis AG, Mathias EG, Dutcus, et al. Response to lenvatinib treatment in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC): updated results from SELECT. J Clin Oncol 34, 2016 (suppl; abstr 6089).
  4. Brose MS, Nutting C, Jarzab B, et al. Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial. J Clin Oncol 31, 2013 (suppl; abstr 4).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
Publication Bottom Border
Border Publication